Immunocore Holdings (IMCR) Stock Forecast: StockMap's 2-Week Call
IMCR stock forecast: StockMap's model makes no two-week call on Immunocore Holdings after the Nov 13 close: its evidence is split, 4 reasons for and 11 against. Too few two-week windows graded to judge yet.
Immunocore Holdings last closed at $29.94, -1.77% on the session.
Against the IVW growth benchmark the position is -0.86% over the forecast window.
Immunocore Holdings' market cap is $1.57B as of November 13, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -15 (too close to call).
Where IMCR sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 4 bullish and 11 bearish.
Agreement across those insights is 73%.
9 daily calls for IMCR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Immunocore Holdings in the 35th percentile on return on equity, where 100 is best.
Immunocore Holdings is classified under Health Care / Biotechnology.
StockMap tracks Immunocore Holdings as the 106th largest of the 391 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 186 Moderate Underperform, 157 Neutral, 33 Strong Underperform and 15 Moderate Outperform.
On that composite Immunocore Holdings ranks 144th of 391 in the group, against a group median of -0.24.